Trusted Resources: Education
Scientific literature and patient education texts
Risdiplam for the Use of Spinal Muscular Atrophy
source: Orthopedic Reviews
year: 2021
authors: Kakazu J, Walker NL, Babin KC, Trettin KA, Lee C, Sutker PB, Kaye AM, Kaye AD
summary/abstract:Spinal muscular atrophy (SMA) is one of the leading causes of death in infants related to the degeneration of neurons. Currently, there are no curative treatment options for SMA, and many options available may not be feasible. This review presents the background, clinical studies, and indications for the use of Risdiplam in treating SMA. SMA causes a decrease in the production of survival motor neuron proteins (SMN) and current treatments target to increase the expression of SMN. Risdiplam is the first and only oral medication to be approved to treat SMA. As an SMN2 splicing modifier, it has provided stronger systemic therapies than previous intrathecal and gene replacement therapies. There have been many efforts to treat SMA with multidisciplinary approaches. These include intrathecal injections to gene replacement therapies. However, these have been faced with limitations such as reaching a good therapeutic dose in systemic tissues, route of administration, and price. Risdiplam is currently the only orally administered drug approved by the FDA for the treatment of SMA. It not only provides a good therapeutic window to systemic tissues but allows for a non-invasive approach in infants. Further investigation and comparison on the safety profile of Risdiplam due to its broader systemic effect should be considered with other available therapies.
organization: Georgetown University School of Medicine, USA; Louisiana State University Health Sciences Center, USA; Creighton University School of Medicine-Phoenix Regional Campus, USA; University of the Pacific, USADOI: 10.52965/001c.25579
read more
Related Content
-
Once-Daily Risdiplam Beneficial in Patients With Types 2 and 3 SMA: LancetOnce-Daily Risdiplam is beneficial in pa...
-
Spinal Muscular Atrophy: From Rags to RichesThe aim of this paper is to provide a sh...
-
What It Is Like to Have a Rare Disease. How Clinical Trials Changed My Life?When I was about 1, I started walking wi...
-
FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants With Spinal Muscular Atr...PTC Therapeutics, Inc. announced that th...
-
Every Day You Don’t Lose, You Are WinningJennifer Summers, 35, is an optimistic, ...
-
Spinal Muscular Atrophy 2020: SMA Medications for Treatment Updateshttps://www.youtube.com/watch?v=dnSXnvrO...
-
Lunch & Learn: Gene Therapy for SMAhttps://www.youtube.com/watch?v=YFEMR1ZH...